Mirum Pharmaceuticals, Inc.
MIRM
Rangering i aksjer
#3243
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to... Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
Aksjekurs
$83.62
Sist synkronisert: 2026-10-21
Markedsverdi
$5.43B
Endring (1 dag)
-1.71%
Endring (1 år)
20.14%
Land
US
Handel Mirum Pharmaceuticals, Inc. (MIRM)
Kategori
Healthcare
Aksjeprishistorikk for Mirum Pharmaceuticals, Inc. (MIRM)
Høyeste sluttskurs: $82.31 den 2026-10-01
Laveste sluttskurs: $13.66 den 2019-07-01
Laveste sluttskurs: $13.66 den 2019-07-01
Aksjeprishistorikk for Mirum Pharmaceuticals, Inc. fra 2019 til 2026
Årlig aksjeprisytelse
| År | Ytelse |
|---|---|
| 2026 (TTM) | 28.91% |
| 2025 | 68.24% |
| 2024 | 35.06% |
| 2023 | 73.09% |
| 2022 | 24.19% |
| 2021 | -29.47% |
| 2020 | 29.71% |
| 2019 | 0.00% |
Aksjepris for lignende selskaper eller konkurrenter
| Selskap | Aksjepris | Endring 1år% | Land |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $757.97 | 7.73% |
CH
|
